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Abstract
Objective
Early diagnosis is has a crucial role in both prevention and treatment 
of asphyxia-related complications. The current study aimed to 
evaluate the prognostic value of interleukin-6 (IL-6) and hypoxic-
ischemic encephalopathy grade in the prediction of mortality and 
the developmental status of neonates affected by prenatal asphyxia. 
Materials & Methods
This cohort study was conducted on 38 term asphyxiated infants 
at Ghaem hospital, Mashhad, Iran, from 2013 to 2017. The HIE 
grade and serum IL-6 levels were determined at the time of birth. 
The developmental status was evaluated using the Denver II test at 
the end of the two-year follow-up. 
Results
HIE grade 3 resulted in 83% mortality rate and developmental 
delay among all survivors. The mean IL-6 level was 2.7 ng/ml in 
the control group (not affected HIE), which increased up to 29, 175, 
and 136 ng/ml in those with HIE grades of 1, 2, and 3, respectively. 
According to the ROC curve analysis, the cut-off level of 24 pg/
ml could predict the developmental delay with sensitivity and 
specificity of 96 and 92%, respectively. 
Conclusion
The IL-6 level and HIE grade are potential prognostic biomarkers 
for the determination of mortality and morbidity in asphyxiated 
neonates.
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Despite advances in perinatal care, asphyxia 
is a major cause of mortality and permanent 
neurological as well as developmental 
complications in neonates (1). According to the 
World Health Organization (WHO), mild-to-
severe asphyxia occurs in 3% (6.3 million cases) of 
newborns, born in developing countries. It claims 
840,000 lives and causes severe consequences in 
almost all survivors (2).
Perinatal asphyxia may result in multi-organ 
complications like respiratory distress syndrome, 
disseminated intravascular coagulation (DIC), 
subcutaneous fat necrosis, myocardial ischemia, 
adrenal hemorrhage, metabolic disorders, and acute 
tubular necrosis. Although most of the consequences 
are transient, asphyxia may cause hypoxic ischemic-
encephalopathy (3). The prevalence of perinatal 
asphyxia in East and Central Africa was 15.9%.
Workineh, Y., Semachew, A., Ayalew, E., Animaw, 
W., Tirfie, M., & Birhanu, M. (2020). Prevalence 
of perinatal asphyxia in East and Central Africa: 
systematic review and meta-analysis. Heliyon, 6(4), 
e03793. (4) and may have consequences such as 
cerebral palsy, epilepsy, and learning disabilities (2, 
5). Therefore, prediction of prognosis of asphyxia 
is a priority for both prevention and treatment of its 
complications (6).
Currently, the diagnosis of asphyxia is based on 
electronic fetal monitoring during labor, presence 
of meconium in the amniotic fluid, Apgar score, 
signs of HIE (7, 8), and multi-organ disorder 
within 72 hours after delivery. These clinical 
symptoms are supplemented with laboratory tests 
such as measuring fetal scalp blood pH, arterial 
blood gases testing, nucleated red blood cells, 
and biochemical markers like lactate, lactate 
dehydrogenase (LDH), creatine kinase (CK), 
neuron specific enolase, and several other proteins 
(9). The role of antioxidant-oxidant balance, heat 
shock protein, and interleukins (10) in prognosis of 
asphyxia is evaluated by several studies. 
Hence, determining the prognosis of asphyxia 
is considered a priority for the prevention and 
treatment of its complications (6). There is no 
correlation between current diagnostic criteria and 
patients’ prognosis, and in the absence of reliable 
markers (11), early diagnosis of HIE of asphyxia 
and its related brain damage is a challenging 
task in neonatal care (12). Recently, it has been 
reported that inflammatory cytokines contribute 
to the pathogenesis of ischemic brain injury (13). 
Increased level of IL-1 ß, IL-8, and IL-6 is reported 
in neonates who suffer from asphyxia (14). It is 
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well-documented that IL-6 concentration in the 
cerebrospinal fluid (CSF) is associated with severe 
HIE, brain damage, and neurological outcomes 
(15). In addition, some studies reported increased 
levels of IL-6 and tumor necrosis factor-alpha 
(TNF-α) in the cerebrospinal fluid of infants with 
HIE (16). While both asphyxia and sepsis cause 
increased plasma level of IL-6 concentration, 
TNF-α level is more associated with sepsis (16). 
Serum IL-6 level has been reported to increase 
within the first 24 hours after hypoxic ischemia 
(16). Therefore, measuring the IL-6 level in 
the umbilical cord blood and peripheral blood 
serum has been reported as a relatively simple 
method to predict brain damage and other adverse 
consequences caused by asphyxia (3, 17). In the 
present study, serum level of IL-6 and other clinical 
and laboratory results were evaluated as biomarkers 
for prognosis of perinatal asphyxia, which is a less 
invasive approach. Hence, the current study aimed 
to evaluate the prognostic value of (IL-6) and 
hypoxic-ischemic encephalopathy (3) grade in the 
prediction of mortality and developmental status of 
neonates affected by prenatal asphyxia.
Materials & Methods
Selection of participants
The study protocol of this observational 
(prospective cohort) research is approved by the 
Ethics Committee of the Mashhad University 
of Medical Sciences (IR.MUMS.MEDICAL.
REC.1397.631), Mashhad, Iran. The study was 
conducted from Jan. 2013 to Oct. 2017 on eligible 
patients admitted to the Ghaem Hospital, Mashhad, 
Iran. We also considered a nested case-control 
design that intended to evaluate asphyxiation in 
infants. In addition, the current study intended to 
evaluate the developmental delay (DD) in a two-
year follow-up period. Finally, we analyzed the 
IL-6 levels as a predictor of developmental delay.
Neonates who had at least two of the following 
criteria were considered eligible:
1. Fetal distress (late deceleration, lack of heart rate 
variability, and FHR< 100); 
2. Thick meconium-stained amniotic fluid and 
hypotonia or bradycardia or respiratory distress 
immediately after birth; 
3. Apgar score below 4 within the first minute or an 
Apgar score below 7 within the first 5 minutes. 
4. Those who required cardiopulmonary resuscitation 
for more than 1 minute using oxygen and 
intermittent positive pressure ventilation (IPPV); 
5. Blood pH < 7.2 and base deficit (18) < 12. 
Initially, the objectives of the study were explained 
to all potential participants and, then, if agreeing, 
written informed consent was obtained from 
their parents or guardians. If there were evidence 
of fetal distress or meconium release, parents 
were informed antenatally. Otherwise, parents 
were approached while infants were treating for 
asphyxia. It worth noting that we performed no 
extra intervention. Therefore, the parents were 
only asked to allow the research team to collect 
the necessary data from their infants and also to 
cooperate during the follow-up period. For those 
cases that the consent was obtained within the 
first hour after the birth, the IL-6 was measured in 
the serum sample collected for routine chemistry 
analyses. Exclusion criteria were congenital 
malformations, metabolic disturbances, sepsis, 
congenital or perinatal infections, and maternal 
chorioamnionitis. 
Clinical Examination 
A comprehensive clinical examination was 
performed on all subjects at birth as well as 3 and 
7 days after the birth. It is worth noting that all 
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examinations were performed by a neonatologist. 
According to the Sarnat staging scale, hypoxic-
ischemic encephalopathy (3) was classified as 
mild (Grade 1), moderate (Grade 2), or severe 
(Grade 3) (19). Mild HIE (Grade 1) was defined 
as being hyperalert, irritable, and hyperreflective, 
but no seizure in the first 24 h after the birth. While 
lethargy, hypotonia, hyporeflexia, myosis, and 
seizure were considered as symptoms of moderate 
(Grade 2) HIE. Eventually, severe (Grade 3) HIE 
was defined as apnea, flaccid, frequent seizure, and 
coma.
All eligible infants were followed up for two years 
and their development status was evaluated four 
times with 6-month intervals using the Denver 
Developmental Screening Test II (DDST-II). 
This test is designed to evaluate functions related 
to personal and social, fine motor and adaptive, 
language, as well as gross motor skills (20). 
Abnormal development was defined as mild, 
moderate, or severe if the child had a delay in one, 
two, three, or more domains in the DDST-II test, 
respectively. Eventually, asphyxiated children were 
divided into two groups of normal and abnormal 
development, based on the DDST-II screening. 
Laboratory tests 
Blood samples (1-2 ml) were collected from the 
asphyxiated infant using umbilical blood sampling 
immediately after the birth. The serum was 
separated by centrifugation and stored at -70°C 
before analysis. Serum IL-6 concentration, pH, 
BE, pCO2, pO2, and O2 saturation were measured 
in all Samples. A Sysmex KX-21 Automated 
Hematology Analyzer (Sysmex, Kobe, Japan) was 
used for cell counting. Arterial blood gas (ABG) 
analysis was performed using a GEM Premier 
3000 (Instrumentation Laboratory, Bedford, MA). 
Serum urea and creatinine were estimated using 
a BT 3000 chemistry analyzer (Biotechnica, 
Rome, Italy). Serum IL-6 levels were measured in 
duplicate using an enzyme-linked immunosorbent 
assay (ELISA) kit (Bender Med Systems, GmbH, 
Vienna, Austria). 
Statistical analysis
Data were analyzed using SPSS version 19 (Apache 
Software Foundation, and Chicago, IL, USA) and 
GraphPad Prism (GraphPad Software, San Diego, 
CA). The findings are described using mean ± 
standard deviation (SD). In order to evaluate the 
association between diagnostic markers (i.e. pH, the 
severity of asphyxia, and IL-6), regression models 
were developed. The sensitivity and specificity of 
the IL-6 testing concerning the determination of 
prognosis of asphyxia were evaluated. Statistical 
significance was considered when p-value<0.005. 
Result
Clinical and Laboratory Findings
Initially, 47 asphyxiated neonates were recruited, 
but 16 were removed, 9 due to diagnosis of 
congenital infections, 2 because of inappropriate 
sample collection, and 5 (two with grade 2 and 
three with grade 1 HIE) discontinued during the 
follow-up period. In the present study, the loss to 
follow-up rate was less than 20%. This means that 
the recommended follow-up rate of 60-80% was 
met. Hence, it can be argued that the probability of 
bias has declined significantly. Finally, 38 children 
completed this study, in which 13 (34%) had 
normal and 25 (66%) abnormal development.
For those in the normal and abnormal groups, 
the mother age was 25.30±4.90 and 21.50±9.18 
years, respectively, which were not significantly 
different (P > 0.2). As presented in Table 1, there 
was no significant difference between these two 
groups concerning the frequency of pregnancy 
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complications (i.e. diabetes, preeclampsia, 
eclampsia, hypertension) and the type of delivery. 
Of 13 children with abnormal development, 6 
(46%) did not have a history of HIE, 6 (46%) had 
HIE grade 1, and one infant (8%) had grade 2 HIE. 
However, all infants in the abnormal development 
group had a history of HIE; 3 infants (12%) grade 
1, 10 (40%) grade 2, and 12 (48%) grade 3. Nearly 
75% of those in this group had a history of the need 
for mechanical ventilation. Finally, 5 cases (20%) 
suffered from mild, three (12%) moderate, and 
three (12%) severe developmental delay, and 14 
children (56%) died during the study period (Table 
1).
There was no significant difference concerning the 
neonatal weight, fifth minute Apgar score, duration 
of hospital stay, white blood cell and platelet 
counts (WBC and PLT), sodium, potassium, Base 
Excess, HCO3
-, and pCO2 between the study groups 
(p>0.05, Table 2). However, these two groups were 
different concerning the severity of HIE (p<0.001), 
serum urea ((p<0.001), and creatinine (p<0.01) as 
well as arterial pH (p <0.005), all measurements 
were performed one hour after the birth.  
The effects of HIE grade variation on surv i val 
(panel A) and prevalence of developmental delay 
(panel B) are shown in Figure 1. While only 11% 
of neonates with HIE grade 1 died and 22% of the 
survivors had mild developmental delay, ab o ut 
27% of the infants with grade 2 eventually  died 
and 60% of the survivors had developmental delay. 
Only 17% of those who were suffering from HIE 
grade 3 survived, in which all had developmental 
delay. There was a direct correlation betw e en 
the severity of HIE and the prevalence of b oth 
developmental delay (p<0.001) and mortality rate. 
The correlation rates between HIE grade wi t h 
mortality rate and developmental delay wer e  84 
and 99%, respectively. 
Correlation between IL-6 Concentration and 
HIE grade
IL-6 concentration in the asphyxiated neonates 
with different grades of HIE is shown in Figure 
2. According to the findings, the mean level of 
IL-6 was increased from 2.7 in the control group 
(not affected HIE) to 29, 175, and 136 ng/ml in 
those with HIE grades of 1, 2, and 3, respectively. 
Hence, HIE grade 1 did not significantly change 
the IL-6 level ((p> 0.1). It also suggests that 
IL-6 concentration may reach its maximum in 
neonates with HIE grade 2. Therefore, there was 
no significant difference concerning the IL-6 
concentration between those with HIE grades of 2 
and 3 (p> 0.2). 
Correlation between IL-6 Concentration and 
Developmental Delay
As shown in Figure 3, there was a statistically 
significant difference concerning the mean IL-6 
concentrations between the control group with 
the normal outcome (no developmental delay) 
and those with different levels of developmental 
delay. While, initially, the IL-6 level was 4 (No 
developmental delay), it increased up to 50, 173, 
and 225 ng/ml in those with mild, moderate, and 
severe developmental delay, respectively. There 
was a direct correlation (96%) between IL-6 level 
and the severity of the developmental delay. Further 
analysis showed that the cut-off levels of 25, 62, 
and 101 pg/ml for predicting mild, moderate, and 
severe developmental delay. Serum IL-6 level had a 
median of 112 and 42 among deceased participants 
who had HIE grades of 2 or 3. 
ROC curve analysis (Fig. 4) indicated that IL-6 
concentration above 24 pg/ml could predict 
the developmental delay with sensitivity and 
specificity of 96 and 92%, respectively. 
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* Pregnancy complications (i.e. diabetes mellitus, pre-eclampsia, eclampsia, and hypertension)
Table 2: Comparing clinical and laboratory parameters between the study groups; 
Normal Development (n=13, 34%) Abnormal Development 
(n=25, 66%)
p-value
Weight (g) 3432± 1156 3362±1007 0.872
One-minute Apgar 5.1± 2.1 4.1±1.6 0.136 
Five-minute Apgar 6.8 ± 2.8 5.6 ± 1.7 0.116 
Length of stay (day) 11.00 ± 2.4 13.3 ± 3.1 0.642
IPPV (h) 54.8 ± 15.1 85.6 ± 21.8 0.003
WBC (x1000) 15.3 ± 5.8 23.1 ± 10 0.065
Plt (x1000) 218±36 164± 75 0.362
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Urea (mg/dl) 18±8 43±25 0.001
Creatinine (mg/dl) 0.5 ± 0.2 1 ± 0.5 0.007
pH 7.25 ± 0.1 7.00± 0.2 0.001
The hematological and chemistry analyses were performed within the first hour after the birth. The values are presented as 
Mean±SD. IPPV: Intermittent Positive Pressure Ventilation, WBC: White Blood Cells, Plt: Platelet, BE: Base Excess.
Figure 1: Effects of HIE grade variation on survival rate (panel A) and prevalence of developmental delay in the survivors (panel B), HIE: hypoxic-
ischemic encephalopathy; Dev Delay: percentage of survivors with developmental delay
Figure 2: Interleukin-6 concentration in the asphyxiated neonates with different grades of hypoxic-ischemic encephalopathy (3). Data are presented 
using the mean values of the IL-6 concentration ± SEM. *** Indicates a statistically significant difference (P<0.001) in IL-6 concentration in NO HIE 
group and those with HIE grades of 2 and 3.
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Discussion
To improve the management procedures, many 
attempts have been made to accurately predict the 
prognosis of asphyxiated neonates by combining 
the results of clinical examinations with laboratory 
Figure 3: Comparing the mean IL-6 concentrations among participants with different outcomes, The study groups included an observational 
category with no development delay (No DD); Mild DD: Mild developmental delay; and Mod. DD: moderate developmental delay; Sev. DD: Sever 
developmental delay; Dead: died during the two-year follow-up period. Data presented as the Mean values of the IL-6 concentration ± SEM. * and ** 
indicate a statistically significant difference in IL-6 concentration with p-values less than 0.05 and 0.01, respectively.
Figure 4: ROC curve analysis of the IL-6 levels for prediction of developmental delay. The level of IL-6 was measured in the asphyxiated infant 
using umbilical blood sampling immediately after delivery. Developmental delay was evaluated using the Denver Developmental Screening Test II 
(DDST-II) after two years of follow-up.
tests. Similar studies mentioned HIE grade, 
5-minutes Apgar score, need for ventilation, 
initial arterial pH, and the severity and duration of 
antepartum metabolic acidosis as important factors 
in the determination of prognosis of asphyxiated 
infants (21). 
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In earlier studies, the combination of serum levels 
of IL-6 (>41 pg/ml) along with moderate to severe 
HIE has been suggested as a prognostic biomarker 
for diagnosis of developmental delay and even 
early death (27). The current study provided 
more details about the merits of combining IL-6 
concentration and HIE grade in the determination 
of asphyxia-related mortality and morbidity rates. 
Regardless of the first hour IL-6 concentration, 
83% of the neonates with HIE grade of 3 would die 
within two years and all survivors will probably 
develop severe developmental delay. IL-6 is highly 
valuable in the determination of the prognosis of 
survivors. For neonates with an IL-6 level of >25, 
62, and 101pg/ml, the child has mild, moderate, 
and severe developmental delays at the age of 2 
years, respectively.
There is a controversy regarding the role of IL-6 
in the pathogenesis of brain damages caused by 
asphyxia. The rise in IL-6 level may support the 
possible role of this cytokine in the pathogenesis 
of hypoxic-ischemic brain injury (16). However, 
it has been suggested that IL-6 might be released 
as a protective response after hypoxic-ischemic 
brain injury and is involved in the repair process 
in the sub-acute stage of HIE. On one hand, the 
findings of the present study revealed a direct 
correlation between IL-6 concentration and the 
severity of developmental delay, which supports 
its destructive role. On the other side, those who 
deceased had a lower level of IL-6, mainly as a 
consequence of HIE, which suggests its possible 
protective effects. This study demonstrated 
hypoxia stimulates IL-6 production via activation 
of MAP kinase (Mitogen-activated protein kinase), 
HIF-1 (hypoxia-inducible factor-1), and NF-kappa 
B (nuclear Factor-kappa B) (28, 29). However, 
cancer-related studies provided evidence that 
According to the findings, there was no significant 
difference between the asphyxiated newborn with 
normal and delayed development concerning 
the number of leukocytes and platelets, which is 
consistent with a similar study (22). However, 
the results showed that 2 years old children with 
developmental delay had higher neonatal serum 
urea and creatinine level as well as lower initial 
arterial pH, which is consistent with other studies 
(23). According to the previous studies, the fifth 
minute Apgar score and pH were lower in the 
asphyxiated neonates compared to the healthy 
newborns (24). The severity of the HIE was an 
important factor in the prediction of mortality rate 
and developmental delay in the survivors. The 
mortality rate was 11, 27 and 83% among infants 
with HIE grades of 1, 2, and 3, respectively. The 
overall rate of asphyxia-associated death has been 
reported to be about 10-30%, and the prevalence 
of neurological complications among survivors 
ranged from 15 to 45% (21).
In the same vein, another study reported that the 
APGAR scores were mild to normal in 68%, 
moderate in 22%, severe in 10% of asphyxiated 
neonates. Additionally, the SARNAT stages were 
I in 25%, II in 52%, and III in 24% of asphyxiated 
cases. Mortality rates were 66.7% in SARNAT 
stage III, 22.2% in SARNAT stage II, and 11.1% 
in SARNAT stage I (25). However, 50-89% of 
those with grade 3 eventually would die, along 
with severe consequences for the development of 
survivors. While only 9.8% of children with an 
HIE grade of 1 had mental retardation; all neonates 
who suffered from grades of 2 and 3 HIE ended up 
with mental retardation, borderline IQ, and average 
IQ (26). Furthermore, it has been reported that 25-
30% of infants with moderate HIE are predisposed 
to developmental abnormality or even death (27). 
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hypoxia may suppress the immune system (30). 
Our results showed a decrease in the IL-6 level by 
increasing HIE grade from 2 to 3, which suggests 
that while mild to moderate hypoxia can induce 
IL-6 expression. In addition, there was a negative 
association between immunosuppressive effects of 
severe hypoxia and IL-6 expression. 
Due to practical difficulties in the recruitment and 
follow-up stages, a limited number of patients 
were included in some groups, which is a common 
problem in such clinical studies. However, it seems 
that the strong correlation between the variables, 
resulted from the prognostic power of these 
biomarkers, could compensate for the adverse 
effects of that limitation. More comprehensive 
studies may result in establishing a combination of 
HIE grade and IL-6 as prognostic biomarkers for 
neonatal asphyxia. 
In Conclusion
This study revealed more details and suggested 
cut-offs for HIE grades and IL-6 levels, as potential 
prognostic biomarkers for mortality and morbidity 
caused by neonatal asphyxia. When followed for 
two years, neonatal IL-6 concentrations above 
24 nl/L combined with HIE grades of 2 and 3 
and acidosis indicated a high mortality rate and 
developmental delay among survivors. Therefore, 
these three parameters may have a crucial role in 
the identification of those asphyxiated neonates 
who need early intervention to alleviate asphyxia-
related developmental delay.
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